~~<i id='332F60F846'><strike id='332F60F846'><tt id='332F60F846'><pre id='332F60F846'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

explore

comprehensive

author：explore 2025-10-02 21:06:24 - browse：121

In a dark grey suit and light blue button-down shirt, Bill Sibold, CEO of Madrigal Pharmaceuticals, smiles— coverage from STAT — Madrigal CEO Bill Sibold says the company is "interested in the patients who are most in need." Madrigal Pharmaceuticals

The Food and Drug Administration is expected to approve the first medicine developed specifically to treat the serious liver disease known as MASH as soon as this week.

The pill, called resmetirom, is made by Madrigal Pharmaceuticals.

Metabolic dysfunction-associated steatohepatitis, or MASH and previously called NASH, is often associated with obesity. The accumulation of fat in the liver causes inflammation, which leads to fibrosis, or liver scarring, and can progress in more advanced stages to cirrhosis, cancer, and the need for a liver transplant.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Alkermes shareholders re
Next article： Emergency workers more likely to restrain Black patients: study

hotspot

Wikipedia

entertainment

leisure time

AdobeYearsofpolarizingscientificdiscourseandbruisingonlinedebatewillcometoaheadnextweekwhenadviserst

WSS

Listen: Covid's latest surge, Alnylam at the FDA, & the end of an era

Microbiome research is starting to find links to chronic diseases

FDA panel endorses Alnylam’s heart drug — after picking it apart

Will the IRA bring competition to the biologics market?

PEPFAR is under serious threat — and so is global health

How AI helped researchers track recovery from depression

explore

comprehensive

hotspot

Drug repurposing or repositioning? The language matters

Readout LOUD podcast: possible new ALS drug, artificial wombs

23andMe had bad news about my health. I wish a person had delivered it

Readout LOUD podcast: possible new ALS drug, artificial wombs

BioMarin wins approval for gene therapy to treat hemophilia A

New Covid vaccine is recommended for everyone 6 months or older

After affirmative action ruling, medical educators look to 'holistic review'

Why are Kaiser Permanente staff considering a strike?

How to save PrEP access — and even expand it

Food makers to regulators: Ultra

hotspot

Experts study whether long Covid risk adds up with each reinfection

IRA could hurt research into orphan drugs for rare diseases

Will the IRA bring competition to the biologics market?

Readout LOUD podcast: possible new ALS drug, artificial wombs

Experts study whether long Covid risk adds up with each reinfection

Biotech lab space demand falls sharply

hotspot

Wikipedia

entertainment

leisure time